JP Morgan Chase’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
– Sell
-4,400
Closed -$427K – 6062
2019
Q3
$427K Buy
+4,400
New +$441K ﹤0.01% 4242
2019
Q2
– Sell
-63,500
Closed -$7.23M – 6150
2019
Q1
$7.23M Buy
+63,500
New +$4.67M ﹤0.01% 2310
2018
Q4
– Sell
-30,000
Closed -$1.64M – 6067
2018
Q3
$1.64M Buy
30,000
+3,000
+11% +$205K ﹤0.01% 3600
2018
Q2
$2.23M Sell
27,000
-3,000
-10% -$232K ﹤0.01% 3335
2018
Q1
$2M Buy
+30,000
New +$1.73M ﹤0.01% 3271

JP Morgan Chase's ONCE Position: Q4 2019 in Review

JP Morgan Chase sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 499,936 shares — an estimated $48.5M sold.

JP Morgan Chase first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $191M in Q2 2018. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.

  • JP Morgan Chase reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • JP Morgan Chase sold 499,936 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $48.5M.
  • JP Morgan Chase first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
  • JP Morgan Chase's Spark Therapeutics, Inc. Common Stock position peaked at $191M in Q2 2018.
  • 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.

Based on JP Morgan Chase's 13F filing for Q4 2019, filed 11 Feb 2020.